V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20214595 | 20080858 | 1.66 | 55.9 | Curative (C) | 2018-08-17 | 2018-09-13 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100918143 |
| 20214596 | 20080859 | null | null | Palliative (P) | 2018-11-27 | 2018-11-27 | LANREOTIDE | N | N | LANREOTIDE | 101680235 |
| 20214599 | 20080860 | 1.8 | 48.95 | Palliative (P) | 2020-02-19 | 2020-02-19 | LANREOTIDE | 02 | N | LANREOTIDE | 100869229 |
| 20214600 | 20080861 | 1.8 | 50 | Palliative (P) | 2022-01-08 | 2022-01-11 | LANREOTIDE | N | N | LANREOTIDE | 100275949 |
| 20214601 | 20080862 | 1.61 | 73.2 | Palliative (P) | 2016-08-15 | 2016-09-01 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101834614 |
| 20214602 | 20080863 | 1.57 | null | Curative (C) | 2017-07-25 | 2017-08-21 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100478831 |
| 20214605 | 20080864 | 1.68 | 71.8 | Adjuvant (A) | 2016-10-28 | 2016-10-30 | IMATINIB | N | N | IMATINIB | 100287661 |
| 20214607 | 20080866 | 1.7 | 67.5 | Palliative (P) | 2018-03-03 | 2018-03-12 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 100330870 |
| 20214608 | 20080867 | 1.51 | 46 | Curative (C) | 2020-06-21 | 2020-07-11 | Cape+Cisplatin+Trastuzumab Load | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 100501329 |
| 20214609 | 20080868 | 1.66 | 114 | Palliative (P) | 2018-09-07 | 2018-09-07 | Trial Unspecified | Y | N | TRIAL | 100803492 |
| 20214610 | 20080869 | 1.85 | 82 | Palliative (P) | 2017-07-17 | 2017-07-17 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100087263 |
| 20214611 | 20080870 | 1.72 | 59.2 | Palliative (P) | 2020-11-17 | 2020-12-04 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100556243 |
| 20214613 | 20080872 | 1.76 | 0 | Not known (9) | 2017-06-20 | 2017-06-20 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100052392 |
| 20214614 | 20080873 | 1.7 | 0 | Palliative (P) | 2016-10-01 | 2016-10-09 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 101576131 |
| 20214616 | 20080875 | null | null | null | 2017-11-06 | 2017-12-06 | LANREOTIDE | 02 | null | LANREOTIDE | 101001753 |
| 20214618 | 20080876 | 0 | 89.2 | Neo-adjuvant (N) | 2020-02-13 | 2020-02-14 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 100542583 |
| 20214619 | 20080877 | 1.73 | 97 | Palliative (P) | 2017-04-25 | 2017-04-25 | Trial Unspecified | 02 | N | TRIAL | 100602166 |
| 20214620 | 20080878 | 1.76 | 59.7 | Curative (C) | 2021-02-03 | 2021-02-09 | Cape+Cisplatin+Trastuzumab Load | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101273015 |
| 20214622 | 20080879 | 1.89 | 64 | Palliative (P) | 2018-02-20 | 2018-03-14 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 101466727 |
| 20214624 | 20080880 | 1.79 | null | Palliative (P) | 2019-03-14 | 2019-04-03 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100666496 |
| 20214625 | 20080881 | null | null | Palliative (P) | 2020-03-19 | 2020-03-23 | Imatinib 400mg | 02 | N | IMATINIB | 100535064 |
| 20214626 | 20080882 | 1.62 | 83.6 | Curative (C) | 2016-07-18 | 2016-08-15 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101834859 |
| 20214627 | 20080883 | 1.66 | 0 | Disease modification (D) | 2018-08-07 | 2018-08-07 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 101833304 |
| 20214629 | 20080884 | 1.5 | 88 | Curative (C) | 2016-07-31 | 2016-08-19 | FLUOROURACIL + MITOMYCIN + RT | null | Y | FLUOROURACIL + MITOMYCIN + RT | 101453309 |
| 20214630 | 20080885 | null | null | Palliative (P) | 2018-07-24 | 2018-07-24 | LANREOTIDE | 99 | N | LANREOTIDE | 100558981 |
| 20214632 | 20080886 | 1.66 | 103.35 | null | 2017-12-30 | 2017-12-30 | LANREOTIDE | 02 | N | LANREOTIDE | 101267862 |
| 20214633 | 20080887 | 1.6 | 81 | Curative (C) | 2016-03-01 | 2016-03-21 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100171147 |
| 20214635 | 20080888 | 1.71 | 105.6 | Curative (C) | 2017-02-26 | 2017-03-24 | Cape+Cisplatin+Trastuzumab Load | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101666984 |
| 20214638 | 20080890 | 1.61 | 118.6 | Palliative (P) | 2018-07-24 | 2018-07-27 | HCX (Cape + Cisp + Tras) - Main | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100760068 |
| 20214639 | 20080891 | 1.73 | 78 | Palliative (P) | 2016-12-30 | 2017-01-01 | GO2 TRIAL | Y | N | TRIAL | 101060334 |
| 20214641 | 20080893 | 1.74 | 97 | Palliative (P) | 2019-12-17 | 2020-01-03 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100831800 |
| 20214642 | 20080894 | 1.7 | 50.1 | Palliative (P) | 2020-01-10 | 2020-01-31 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 100804160 |
| 20214643 | 20080895 | 1.63 | 83 | Disease modification (D) | 2016-02-02 | 2016-02-16 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101108529 |
| 20214644 | 20080896 | 1.72 | null | Curative (C) | 2018-10-17 | 2018-10-18 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100175072 |
| 20214645 | 20080897 | 1.76 | 99.3 | Curative (C) | 2017-08-03 | 2017-08-13 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 100980522 |
| 20214646 | 20080898 | null | 71.6 | Disease modification (D) | 2017-01-21 | 2017-01-21 | LANREOTIDE | 02 | N | LANREOTIDE | 100200936 |
| 20214647 | 20080899 | 1.78 | 90.1 | Palliative (P) | 2018-11-23 | 2018-12-02 | GO2 TRIAL | 1 | N | TRIAL | 100991942 |
| 20214648 | 20080900 | 1.57 | 62.1 | Curative (C) | 2016-07-02 | 2016-08-16 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | FLUOROURACIL + MITOMYCIN + RT | 100097274 |
| 20214649 | 20080901 | 1.59 | 81.6 | Adjuvant (A) | 2017-02-25 | 2017-02-25 | GO2 TRIAL | 01 | N | TRIAL | 101276412 |
| 20214651 | 20080902 | 1.76 | 67.1 | Palliative (P) | 2017-04-06 | 2017-04-22 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100533699 |
| 20214652 | 20080903 | null | null | Unknown (U) | 2018-04-23 | 2018-05-24 | LANREOTIDE | 02 | N | LANREOTIDE | 100197956 |
| 20214653 | 20080904 | 1.83 | 88 | Palliative (P) | 2016-04-10 | 2016-04-12 | IMATINIB | 02 | N | IMATINIB | 100934427 |
| 20214654 | 20080905 | 1.6 | 59.9 | Palliative (P) | 2017-04-30 | 2017-05-06 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100372165 |
| 20214655 | 20080906 | 1.5 | 75.5 | null | 2017-09-05 | 2017-09-06 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | IMATINIB | 101085675 |
| 20214656 | 20080907 | 0 | 71.8 | Palliative (P) | 2018-04-20 | 2018-04-20 | LANREOTIDE | 02 | N | LANREOTIDE | 100471389 |
| 20214658 | 20080908 | null | 72 | Palliative (P) | 2018-07-29 | 2018-08-12 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 101467283 |
| 20214659 | 20080909 | 1.8 | 85.5 | Palliative (P) | 2020-04-05 | 2020-04-26 | Cape+Cisplatin+Trastuzumab Load | 02 | N | IMATINIB | 100013801 |
| 20214660 | 20080910 | 1.57 | 0 | Palliative (P) | 2018-06-29 | 2018-07-02 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100649441 |
| 20214661 | 20080911 | 0 | null | Palliative (P) | 2018-05-13 | 2018-05-20 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 100720624 |
| 20214663 | 20080912 | 1.81 | 63.1 | Palliative (P) | 2018-06-04 | 2018-07-07 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100629002 |